Source: MariMed.
  • MariMed (MRMD) and Emack & Bolio’s have released a line of vegan cannabis-infused ice cream
  • Flavors include Cup O’ Coffee Chip and Chocolate Sunny Days
  • The line debuted this week in Massachusetts with additional flavors and wider availability planned over the coming months
  • MariMed is a multi-state U.S. cannabis operator managing numerous seed-to-sale facilities
  • MariMed (MRMD) closed unchanged trading at $0.85 per share

MariMed (MRMD) and Emack & Bolio’s have released a line of vegan cannabis-infused ice cream.

Boston’s Emack & Bolio’s is a globally beloved ice cream brand created in 1975 by music attorney Bob Rook.

The new line is an extension of MariMed’s top-selling and award-winning Betty’s Eddies infused fruit chews. The ice cream combines full spectrum cannabis oil with natural cannabinoids and terpenes into two flavors, Cup O’ Coffee Chip and Chocolate Sunny Days, which debuted at the company’s Panacea Wellness dispensary in Massachusetts this week.

MariMed intends to release additional flavors and expand availability in the coming months.

“We pushed ourselves to make our infused cannabis ice cream as delicious as the best-tasting, non-infused products found in local specialty ice cream stores,” stated Tim Shaw, MariMed’s COO. “With thanks to the Emack & Bolio’s ice cream magicians and our own rock star team, this new ice cream exceeds that high-quality benchmark.”

MariMed is a multi-state U.S. cannabis operator managing numerous seed-to-sale facilities.

MariMed (MRMD) closed unchanged trading at $0.85 per share.


More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.